Classifications

• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
  • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
  • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
  • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
  • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/724—Cyclodextrins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

• the propylene oxide: anhydroglucose molar ratio used is chosen from a range going from 0.70: 1.00 to 0.86: 1.00;
• This chloride content can be conventionally determined by a person skilled in the art by potentiometric titration of an h ⁇ CD solution using a silver nitrate solution of known concentration.
• the HPpCD according to the invention has a pH in a range from 5.0 to 7.5; said pH being measured on the basis of a solution of HP CD consisting of 2 g of dry HP CD, 98 g of distilled water and 0.3 ml of a potassium chloride solution at 225 g / L .
• the propylene oxide: anhydroglucose molar ratio used is greater than or equal to 0.75: 1.00, preferably greater than or equal to 0.80: 1.00, preferably greater than or equal to 0.82: 1.00, preferably greater than or equal to 0.84: 1.00, preferably equal to 0.85: 1, 00.
• the invention also relates to the use of an HRbO ⁇ according to the invention as an excipient, and / or for encapsulating a substance, and / or solubilizing a substance in an aqueous medium, and / or for improving the chemical stability of a substance , and / or to improve the delivery of a substance to and through biological membranes, and / or to increase the physical stability of a substance, and / or to formulate a substance from a liquid form to a pulverulent form , and / or to prevent interactions of a substance with another substance, and / or to reduce local irritation after topical or oral administration of a substance, and / or to prevent absorption of a substance by level of certain tissues such as the skin, and / or to obtain a prolonged release of a substance, and / or to mask the taste of a substance, in particular its bitterness, and / or to mask the smell of a substance , and / or for mo identify the bioavailability of a substance.
• these substances are lipophilic compounds or carriers of at least one lipophilic group.
• the bleaching step was carried out by treatment with active charcoal for 1 h at 70 ° C.
• the medium was then filtered through a bag filter and then a cartridge filter 1 ⁇ m then 0.22 ⁇ m.
• the membrane purification step was carried out using a nanofiltration module equipped with a membrane having a cutoff threshold of less than 800 Da, at a pressure of less than 35 bars and at a temperature of more than 45 ° C. .
• the propanediol content of the retentate was checked by HPLC assay. The nanofiltration operation was stopped as soon as a propanediol content of less than 0.1% by weight on dry product was reached.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Inorganic Chemistry (AREA)
• Materials Engineering (AREA)
• Polymers & Plastics (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biochemistry (AREA)
• Biomedical Technology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Cardiology (AREA)
• Psychiatry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Medicinal Preparation (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Cosmetics (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Steroid Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=67551566

Family Applications (1)

Country Status (10)

Families Citing this family (3)

Family Cites Families (17)

• 2019
  • 2019-06-28 MX MX2020013689A patent/MX2020013689A/es unknown
  • 2019-06-28 US US17/255,153 patent/US12522670B2/en active Active
  • 2019-06-28 WO PCT/FR2019/051602 patent/WO2020002851A1/fr not_active Ceased
  • 2019-06-28 SG SG11202013126QA patent/SG11202013126QA/en unknown
  • 2019-06-28 CN CN201980044053.4A patent/CN112334494A/zh active Pending
  • 2019-06-28 EP EP19752213.9A patent/EP3814386A1/fr active Pending
  • 2019-06-28 JP JP2020573107A patent/JP7581055B2/ja active Active
  • 2019-06-28 KR KR1020207037131A patent/KR102912248B1/ko active Active
  • 2019-06-28 CA CA3104568A patent/CA3104568A1/fr active Pending
• 2020
  • 2020-12-29 IL IL279845A patent/IL279845A/en unknown
• 2024
  • 2024-08-07 JP JP2024130931A patent/JP2024150779A/ja active Pending

Also Published As

Similar Documents

Legal Events